Compellis Pharmaceuticals Overview

  • Founded
  • 2002
Founded
  • Status
  • Out of Business
  • Employees
  • 74
Employees
  • Latest Deal Type
  • Out of Business

Compellis Pharmaceuticals General Information

Description

Developer of therapeutic drugs intended to treat obesity and related disorders. The company's therapeutic drugs block calcium channel that decreases caloric intake by reducing olfactory function, enabling patients to achieve a reduction in food intake, thereby leading to a desired weight reduction and better quality of life.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 141 PowderHouse Boulevard
  • Suite 1
  • Boston, MA 02144
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Compellis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Apr-2016 Completed Out of Business
1. Early Stage VC Completed Startup
To view Compellis Pharmaceuticals’s complete valuation and funding history, request access »

Compellis Pharmaceuticals Patents

Compellis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20050191245-A1 Increases amount of drug (verapamil, diltiazem, cinnarizine or nifedipine) delivered to the brain of a patient Abandoned 27-Feb-2004 0000000000 0
US-20040167117-A1 Calcium channel blockers administered into nose Granted 18-Feb-2003 0000000000 00
US-7138107-B2 Calcium channel blockers administered into nose Expired - Fee Related 18-Feb-2003 0000000000 00
US-7435407-B2 Intranasal administration of an l-type cyclic-nucleotide-gated calcium channel blocker, verapamil, amlodipine, nimodipine, israpidine; atherosclerosis, coronary artery disease, hypertension, hypercholesterolemia, diabetes mellitus, gout, osteoarthritis, intertrigo, sleep apnea, hyperlipidemia Expired - Fee Related 09-Dec-2002 0000000000
US-20070025921-A1 Intranasal administration of an l-type cyclic-nucleotide-gated calcium channel blocker, verapamil, amlodipine, nimodipine, israpidine; atherosclerosis, coronary artery disease, hypertension, hypercholesterolemia, diabetes mellitus, gout, osteoarthritis, intertrigo, sleep apnea, hyperlipidemia Granted 09-Dec-2002 A61K9/0043

Compellis Pharmaceuticals Executive Team (1)

Name Title Board Seat Contact Info
Christopher Adams Founder, Chief Executive Officer & President
To view Compellis Pharmaceuticals’s complete executive team members history, request access »

Compellis Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial